adjuvanted trivalent influenza vaccine

Developed for: influenza
Investigated by: Brown University · Case Western Reserve University · Insight Therapeutics, LLC · Seqirus

today NCT02882100 · Ph 4

201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 4	NCT02882100	Apr 2016 → Oct 2018	influenza	Insight Therapeutics, LLC	Completed	Met primary

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	adjuvanted trivalent influenza vaccine	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02882100 ↗
Modality	Vaccine	“adjuvanted trivalent influenza vaccine (aTIV; FLUAD)” NCT02882100 ↗